Yeast Bloodstream Infections in the COVID-19 Patient : A Multicenter Italian Study (FiCoV Study)
Fungemia is a co-infection contributing to the worsening of the critically ill COVID-19 patient. The multicenter Italian observational study FiCoV aims to estimate the frequency of yeast bloodstream infections (BSIs), to describe the factors associated with yeast BSIs in COVID-19 patients hospitalized in 10 hospitals, and to analyze the antifungal susceptibility profiles of the yeasts isolated from blood cultures. The study included all hospitalized adult COVID-19 patients with a yeast BSI; anonymous data was collected from each patient and data about antifungal susceptibility was collected. Yeast BSI occurred in 1.06% of patients, from 0.14% to 3.39% among the 10 participating centers. Patients were mainly admitted to intensive or sub-intensive care units (68.6%), over 60 years of age (73%), with a mean and median time from the hospitalization to fungemia of 29 and 22 days, respectively. Regarding risk factors for fungemia, most patients received corticosteroid therapy during hospitalization (61.8%) and had a comorbidity (25.3% diabetes, 11.5% chronic respiratory disorder, 9.5% cancer, 6% haematological malignancies, 1.4% organ transplantation). Antifungal therapy was administered to 75.6% of patients, mostly echinocandins (64.5%). The fatality rate observed in COVID-19 patients with yeast BSI was significantly higher than that of COVID-19 patients without yeast BSI (45.5% versus 30.5%). Candida parapsilosis (49.8%) and C. albicans (35.2%) were the most fungal species isolated; 72% of C. parapsilosis strains were fluconazole-resistant (range 0-93.2% among the centers). The FiCoV study highlights a high prevalence of Candida BSIs in critically ill COVID-19 patients, especially hospitalized in an intensive care unit, a high fatality rate associated with the fungal co-infection, and the worrying spread of azole-resistant C. parapsilosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of fungi (Basel, Switzerland) - 9(2023), 2 vom: 20. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prigitano, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal resistance |
|---|
| Anmerkungen: |
Date Revised 01.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jof9020277 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353425257 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353425257 | ||
| 003 | DE-627 | ||
| 005 | 20231226055950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jof9020277 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353425257 | ||
| 035 | |a (NLM)36836391 | ||
| 035 | |a (PII)277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prigitano, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Yeast Bloodstream Infections in the COVID-19 Patient |b A Multicenter Italian Study (FiCoV Study) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Fungemia is a co-infection contributing to the worsening of the critically ill COVID-19 patient. The multicenter Italian observational study FiCoV aims to estimate the frequency of yeast bloodstream infections (BSIs), to describe the factors associated with yeast BSIs in COVID-19 patients hospitalized in 10 hospitals, and to analyze the antifungal susceptibility profiles of the yeasts isolated from blood cultures. The study included all hospitalized adult COVID-19 patients with a yeast BSI; anonymous data was collected from each patient and data about antifungal susceptibility was collected. Yeast BSI occurred in 1.06% of patients, from 0.14% to 3.39% among the 10 participating centers. Patients were mainly admitted to intensive or sub-intensive care units (68.6%), over 60 years of age (73%), with a mean and median time from the hospitalization to fungemia of 29 and 22 days, respectively. Regarding risk factors for fungemia, most patients received corticosteroid therapy during hospitalization (61.8%) and had a comorbidity (25.3% diabetes, 11.5% chronic respiratory disorder, 9.5% cancer, 6% haematological malignancies, 1.4% organ transplantation). Antifungal therapy was administered to 75.6% of patients, mostly echinocandins (64.5%). The fatality rate observed in COVID-19 patients with yeast BSI was significantly higher than that of COVID-19 patients without yeast BSI (45.5% versus 30.5%). Candida parapsilosis (49.8%) and C. albicans (35.2%) were the most fungal species isolated; 72% of C. parapsilosis strains were fluconazole-resistant (range 0-93.2% among the centers). The FiCoV study highlights a high prevalence of Candida BSIs in critically ill COVID-19 patients, especially hospitalized in an intensive care unit, a high fatality rate associated with the fungal co-infection, and the worrying spread of azole-resistant C. parapsilosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antifungal resistance | |
| 650 | 4 | |a candidemia | |
| 650 | 4 | |a fungemia | |
| 650 | 4 | |a invasive fungal infections | |
| 700 | 1 | |a Blasi, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrò, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Cavanna, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Cornetta, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Grancini, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Innocenti, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Cascio, Giuliana |e verfasserin |4 aut | |
| 700 | 1 | |a Nicola, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Trovato, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Cogliati, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Esposto, Maria Carmela |e verfasserin |4 aut | |
| 700 | 1 | |a Tortorano, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Romanò, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a On Behalf Of The FiCoV Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of fungi (Basel, Switzerland) |d 2014 |g 9(2023), 2 vom: 20. Feb. |w (DE-627)NLM25748468X |x 2309-608X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:2 |g day:20 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jof9020277 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 2 |b 20 |c 02 | ||